Search

Your search keyword '"Loureiro L"' showing total 351 results

Search Constraints

Start Over You searched for: Author "Loureiro L" Remove constraint Author: "Loureiro L"
351 results on '"Loureiro L"'

Search Results

2. Evaluation of Ergonomic Risk of Warehouse Activities in a Telecommunications Sector Company

3. CAR-MEDIATED TARGETING OF NK CELLS OVERCOMES TUMOR IMMUNE ESCAPE CAUSED BY ICAM-1 DOWNREGULATION

4. UniCAR T-cell potency – A matter of affinity between Adaptor Molecules and Adaptor CAR T-cells?

5. From Suppression to T cell Activation: Targeting Immune Checkpoints with the RevCAR System

6. 64Cu tumor labeling with hexadentate picolinic acid-based bispidine immunoconjugates

8. IMPACTOS DA COVID-19 NA SAÚDE DO IDOSO

12. Development of UniCAR TM for targeting of FAP positive cells

13. Targeting immune checkpoint molecules with RevCAR platform for immunotherapy and modulation of the tumor microenvironment

14. Therapeutic targeting and diagnostic imaging of Fibroblast Activation Protein expressing cancers using the UniCAR system

15. AND-Targeting of EpCAM+ and CEA+ colorectal cells using the modular Dual-RevCAR platform

16. Using an Adaptor CAR System to Target Fibroblast Activation Protein for Diagnostic and Therapeutic Purposes

17. Turning an Immunosuppressive Marker Into a T-Cell Activating Signal: Using the RevCAR System to Target Immune Checkpoints

18. Lisbon Summer School - Mid-term check - Innovative Target Modules for FAP-Targeting UniCAR T therapy

19. A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells

20. Targeting colorectal cancer cells using AND-gated Adaptor RevCAR T-cells

21. Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1

22. FLT3-directed UniCAR T-cell therapy of Acute Myeloid Leukaemia

23. Immunotheranostic target modules for imaging and navigation of UniCAR T-cells to strike FAP-expressing cells and the tumor microenvironment

24. Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy

25. Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells

26. Development Of A Novel ACE2 Decoy For Both SARS-CoV-2 Variant Neutralization And Infected Cell Elimination Via Unmodified Or CAR Modified Immune Cells

27. Data publication: Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1

28. Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

29. FLT3‐directed UniCAR T‐cell therapy of acute myeloid leukaemia.

36. Comparison of two structurally different RevTMs for the RevCAR system to specifically target CEA expressing cells

37. Chelator-based non-peptidic radiotracers for PET imaging of PD-L1 with copper-64

38. Immunotheranostic target modules suitable for imaging and navigation of UniCAR T-cells to strike FAP-expressing solid tumours and their microenvironment

39. Adapter CARs: Estimation of the affinity between adapter and CAR domain required for function

40. As small as it can be: short peptide-derived target molecules for redirection of UniCAR T-cells and imaging of SSTR2-expressing cancers

41. UniCAR T cell theranostics for diagnostic imaging and therapy of prostate cancer

42. Antigen-specific redirection of off-the-shelf NK-92 cells using the universal CAR platform ‘‘UniCAR’’

43. The RevCAR T cell platform: a switchable and combinatorial therapeutic strategy for glioblastoma

44. Development and functional characterization of a versatile radio-/immunotheranostic tool for prostate cancer management

45. Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T cells

46. Validation of CD98hc as a therapeutic target for a combination of radiation and immunotherapies in head and neck squamous cell carcinoma

47. Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR)

48. Driving modular CARs through solid tumours and their microenvironment - a new era in cancer immunotherapy

49. CAR Technology Meets Theranostics – A New Era of Immunotheranostics for Hematological and Solid Tumors

50. Adaptor UniCAR and RevCAR platforms for flexible, switchable and combinatorial tumor targeting

Catalog

Books, media, physical & digital resources